|
|
(MedPage Today) -- Prescriptions for fenofibrate (TriCor) and fenofibric acid (Trilipix) tripled from 2002 to 2009 -- even as clinical studies failed to confirm that they reduce cardiovascular events in diabetic patients, researchers said.
Read from Source
|
| |
| |
| | 99 |
| |
|
|
|
|
|
|
